{"schema_version":"secwatch.filing_event.v1","accession":"0000920148-23-000004","form_type":"8-K","ticker":"LH","cik":"0000920148","company_name":"LABCORP HOLDINGS INC.","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.574912+00:00","generated_at":"2026-06-20T20:05:18.470586+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Labcorp appoints Thomas Pike to lead Drug Development unit; will become CEO of spin-off company","bullets":["Thomas Pike appointed President and CEO of Drug Development Clinical Development business, effective Jan 9, 2023.","Upon planned spin-off (expected mid-2023), Pike will become CEO and Chairman of the independent publicly listed company.","Paul Kirchgraber, current EVP and CEO of Drug Development, will depart after the spin-off; he continues leading Early Development, Central Laboratories, and Global Oncology.","Labcorp to announce the new company's Board of Directors, including lead independent director, in coming months."],"urls":{"canonical":"https://secwatch.observer/filing/0000920148-23-000004","json":"https://secwatch.observer/filing/0000920148-23-000004.json","markdown":"https://secwatch.observer/filing/0000920148-23-000004.md","text":"https://secwatch.observer/filing/0000920148-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000004/0000920148-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000004/lh-20230104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T20:05:18.470586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8f341766cc","claim":"Thomas Pike was appointed as President and Chief Executive Officer of Drug Development Clinical Development business unit at LABCORP HOLDINGS INC..","evidence_excerpt":"Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit effective January 9, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000004/0000920148-23-000004-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer of Drug Development Clinical Development business unit"}],"fact_type":"executive_change"},{"claim_id":"c7d9fd71f4","claim":"Paul Kirchgraber departed as EVP and CEO of Drug Development business segment at LABCORP HOLDINGS INC..","evidence_excerpt":"Paul Kirchgraber, EVP and CEO of Labcorp’s Drug Development business segment informed Labcorp that he intends to depart Labcorp upon the completion of the planned spin-off in order to pursue other opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000004/0000920148-23-000004-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"intends to depart"},{"label":"Role","value":"EVP and CEO of Drug Development business segment"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}